Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 13, 2021
High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung CancerRenelle Myers, Michael Brauer, Trevor Dummer, et al.Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)Balazs Halmos, Eng-Huat Tan, Ross A Soo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung CancerBarbara Melosky, Helen Anderson, Ronald L Burkes, et al.Pharmacoeconomics - Open|February 22, 2023
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung CancerAndre Verhoek, Parneet Cheema, Barbara Melosky, et al.BMC Cancer|July 14, 2007
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patientsTrevor J Pugh, Gwyn Bebb, Lorena Barclay, et al.Journal of the National Cancer Institute|January 9, 2026
Targeting common EGFR mutations in NSCLC-review of global phase III trials of third-generation inhibitorsBarbara Melosky, Rosalyn A Juergens, Quincy S C Chu, et al.JTO Clinical and Research Reports|May 20, 2022
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With <i>BRAF</i>-Mutated Advanced NSCLCBruce E Johnson, Christina S Baik, Julien Mazieres, et al.The Oncologist|March 26, 2025
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitisFunda Meric-Bernstam, Aditya Bardia, Paolo Bossi, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidanceKim A Papp, Luis Puig, Jennifer Beecker, et al.JTO Clinical and Research Reports|June 26, 2025
Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer ManagementKassandra R Bisson, Andrea Beharry, Normand Blais, et al.Pageof 8